Psyence Group

Psyence Group, with its slogan "Psyence Group sets the global standard for natural psychedelics," is a pioneering player in the biotechnology sector, focusing on the use of natural psilocybin for mental health and well-being, particularly in palliative care contexts. Founded in 2019, the company is making significant strides towards redefining treatments for mental health through cutting-edge life science innovations.

The company, headquartered in Canada, holds a unique position thanks to its federally licensed psilocybin cultivation and production facility in Southern Africa, one of the first of its kind. This strategic advantage allows Psyence to operate across multiple legal jurisdictions, enhancing its global footprint within the Biotechnology, Health Care, Health and Wellness, and Life Sciences industries.

Psyence is publicly traded on both the Canadian Stock Exchange (CSE) under the symbol PSYG and the US OTCQB® Venture Market under PSYGF. Its capability to attract substantial investment was evident with the latest $25.00M Post-IPO Equity investment from WHITE LION CAPITAL on 31 July 2024, underscoring investor confidence in its business model and future prospects.